Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy After Prostatectomy, a Phase III Randomized Study of Prostatectomy Versus Prostatectomy with Adjuvant Docetaxel for Patients with High-Risk, Localized Prostate Cancer

Urology

Volumn 72, Issue 3, 2008, Pages 474-480

  Montgomery, Bruce ^a   Lavori, Philip ^b   Garzotto, Mark ^c   Lee, Kelvin ^d   Brophy, Mary ^e   Thaneemit Chen, Surai ^d   Kelly, William ^f   Basler, Joseph ^g   Ringer, Robert ^h   Yu, Wei ^d   Whittemore, Alice ^b   Lin, Daniel W ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Massachusetts Veterans Epidemiology Research and Information Center   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g University of Texas Health Science Center   (United States)

^h Clinical Research Pharmacy Coordinating Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RELAPSE; REVIEW;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HOSPITALS, VETERANS; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK; TAXOIDS; TREATMENT OUTCOME;

EID: 50249089542     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.02.050     Document Type: Review

References (42)

1. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141-1147
2. Aranha O., and Vaishampayan U. PSA relapse prostate cancer: the importance of tailored therapy. Urol Oncol 22 (2004) 62-69
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-330
4. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
5. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
6. Cooperberg M.R., Broering J.M., Litwin M.S., et al. The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CapSURE), a national disease registry. J Urol 171 (2004) 1393-1401
7. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
8. Roberts W.W., Bergstralh E.J., Blute M.L., et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 57 (2001) 1033-1037
9. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17 (1999) 1499-1507
10. Bauer J.J., Connelly R.R., Sesterhenn I.A., et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer 79 (1997) 952-962
11. Amling C.L., Bergstralh E.J., Blute M.L., et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 165 (2001) 1146-1151
12. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
13. Kupelian P., Katcher J., Levin H., et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 3 (1997) 78-87
14. Hull G.W., Rabbani F., Abbas F., et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167 (2002) 528-534
15. Grossfeld G.D., Chang J.J., Broering J.M., et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 165 (2001) 851-856
16. Zincke H., Oesterling J.E., Blute M.L., et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152 (1994) 1850-1857
17. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
18. D'Amico A.V., Moul J., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42-S47
19. D'Amico A.V., Moul J.W., Carroll P.R., et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376-1383
20. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71 (2004) 29-33
21. Krupski T.L., Kwan L., Afifi A.A., et al. Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol 23 (2005) 7881-7888
22. Cooperberg M.R., Lubeck D.P., Penson D.F., et al. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs Health Care System: data from CaPSURE. J Urol 170 (2003) 905-908
23. Leventis A.K., Shariat S.F., Kattan M.W., et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19 (2001) 1030-1039
24. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
25. Anscher M.S., Robertson C.N., and Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. Int J Radiat Oncol Biol Phys 33 (1995) 37-43
26. Morris M.M., Dallow K.C., Zietman A.L., et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 38 (1997) 731-736
27. Valicenti R.K., Gomella L.G., Ismail M., et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 45 (1999) 53-58
28. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
29. Swanson G.P. Phase III randomized study of adjuvant radiation therapy versus observation in patients with pathologic T3 prostate cancer (SWOG 8794). Proc Am Soc Ther Radiat Oncol 63 (2005) 16-20
30. Agus D.B., Cordon-Cardo C., Fox W., et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91 (1999) 1869-1876
31. Miayake H., Tolcher A., and Gleave M.E. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 92 (2000) 34-41
32. Krueckl S.L., Sikes R.A., Edlund N.M., et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64 (2004) 8620-8629
33. Rocchi P., Beraldi E., Ettinger S., et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 65 (2005) 11083-11093
34. Wirth M.P., Weissbach L., Marx F.J., et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 45 (2004) 267-270
35. Rapp E., Pater J.L., Willan A., et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 6 (1988) 633-641
36. Ranson M., Davidson N., Nicolson M., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92 (2000) 1074-1080
37. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
38. Moertel C.G., Fleming T.R., MacDonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322 (1990) 352-358
39. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345 (1995) 939-944
40. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
41. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
42. Lara Jr. P.N., and de Vere White R. Accrual issues in genitourinary cancer clinical trials. Urol Oncol 24 (2006) 379-383